AIM: To explore imatinib efficacy and pharmacokinetics in children and adolescents with refractory/relapsing solid tumours, expressing imatinib-sensitive receptor tyrosine kinases. METHODS: Exploratory study on imatinib in tumours expressing, at least, one of the receptors KIT or platelet-derived growth factor receptor (PDGFR). Standard radiological response evaluation, pharmacokinetics, gene mutations and positron emission tomography imaging were assessed. RESULTS: Thirty-six patients (median age: 13.7 years) with brain (12), mesenchymal/bone (14) or other solid tumours, received imatinib 340 mg/m(2)/d over a total of 255 months. Fifteen tumours expressed KIT in 30% cells, 19 expressed PDGFRA and 25 expressed PDGFRB. Twenty patients experienced grades 1-2 treatment-related toxicities. Ten patients achieved stable disease; one chordoma had metabolic response. Pharmacokinetic data showed high inter-patient variability (variation coefficient: 44% and 53% for plasma imatinib and CGP 74588 AUCs, respectively). CONCLUSIONS: Imatinib was tolerated well, but failed to show efficacy according to standard criteria in paediatric malignancies expressing KIT or PDGFR.
AIM: To explore imatinib efficacy and pharmacokinetics in children and adolescents with refractory/relapsing solid tumours, expressing imatinib-sensitive receptor tyrosine kinases. METHODS: Exploratory study on imatinib in tumours expressing, at least, one of the receptors KIT or platelet-derived growth factor receptor (PDGFR). Standard radiological response evaluation, pharmacokinetics, gene mutations and positron emission tomography imaging were assessed. RESULTS: Thirty-six patients (median age: 13.7 years) with brain (12), mesenchymal/bone (14) or other solid tumours, received imatinib 340 mg/m(2)/d over a total of 255 months. Fifteen tumours expressed KIT in 30% cells, 19 expressed PDGFRA and 25 expressed PDGFRB. Twenty patients experienced grades 1-2 treatment-related toxicities. Ten patients achieved stable disease; one chordoma had metabolic response. Pharmacokinetic data showed high inter-patient variability (variation coefficient: 44% and 53% for plasma imatinib and CGP 74588 AUCs, respectively). CONCLUSIONS:Imatinib was tolerated well, but failed to show efficacy according to standard criteria in paediatric malignancies expressing KIT or PDGFR.
Authors: Aleksandra Bielen; Lara Perryman; Gary M Box; Melanie Valenti; Alexis de Haven Brandon; Vanessa Martins; Alexa Jury; Sergey Popov; Sharon Gowan; Sebastien Jeay; Florence I Raynaud; Francesco Hofmann; Darren Hargrave; Suzanne A Eccles; Chris Jones Journal: Mol Cancer Ther Date: 2011-06-09 Impact factor: 6.261
Authors: Viswanath Reddy Belum; Courtney Washington; Christine A Pratilas; Vincent Sibaud; Franck Boralevi; Mario E Lacouture Journal: Pediatr Blood Cancer Date: 2015-02-12 Impact factor: 3.167
Authors: Fiorina Giona; Stefania Mariani; Lucio Gnessi; Maria Luisa Moleti; Massimiliano Rea; Annalisa De Vellis; Deborah Marzella; Anna Maria Testi; Robin Foà Journal: Haematologica Date: 2012-09-14 Impact factor: 9.941
Authors: Oren J Becher; Dolores Hambardzumyan; Talia R Walker; Karim Helmy; Javad Nazarian; Steffen Albrecht; Rebecca L Hiner; Sarah Gall; Jason T Huse; Nada Jabado; Tobey J MacDonald; Eric C Holland Journal: Cancer Res Date: 2010-03-02 Impact factor: 12.701
Authors: Stephanie Puget; Cathy Philippe; Dorine A Bax; Bastien Job; Pascale Varlet; Marie-Pierre Junier; Felipe Andreiuolo; Dina Carvalho; Ricardo Reis; Lea Guerrini-Rousseau; Thomas Roujeau; Philippe Dessen; Catherine Richon; Vladimir Lazar; Gwenael Le Teuff; Christian Sainte-Rose; Birgit Geoerger; Gilles Vassal; Chris Jones; Jacques Grill Journal: PLoS One Date: 2012-02-28 Impact factor: 3.240
Authors: Alberto Broniscer; Sharyn D Baker; Cynthia Wetmore; Atmaram S Pai Panandiker; Jie Huang; Andrew M Davidoff; Arzu Onar-Thomas; John C Panetta; Thomas K Chin; Thomas E Merchant; Justin N Baker; Sue C Kaste; Amar Gajjar; Clinton F Stewart Journal: Clin Cancer Res Date: 2013-03-27 Impact factor: 12.531